Effective acute treatment of migraine is possible with the 5HT(1B/1D) agoni
sts (triptans), but their use has been limited in the UK because of concern
s about limited efficacy, recurrence of attacks, adverse events, and cost.
Almotriptan (Almogran, Lundbeck Ltd, Milton Keynes), the most recently avai
lable member of the class, offers some advantages over previously available
agents.